Figure 5

GPIIb/IIIa blockage reduces the thrombolysis resistance conferred by incubation time. Thrombolysis profiles with 0.7 nM tPA were measured on halo thrombi incubated for 4 hours (aged clots) with different concentration of GPIIb/IIIa blocker Reopro (0, 2.5, 5, 10 and 20 µg/mL) and compared to thrombolysis obtained with 0.7 nM tPA on fresh clots (A). Activation times (B) and maximal clot lysis rates (C) were presented for each group as mean values ± SD (n = 5). Thrombolysis profiles with 20 U/mL urokinase (D) and with 0.1 U/mL plasmin (G) on halo thrombi incubated for 4 hours (aged clots) with or without 20 µg/mL GPIIb/IIIa blocker Reopro and compared to thrombolysis obtained with 20 U/mL urokinase or 0.1 U/mL plasmin respectively. Activation times (E) and maximal clot lysis rates (F) were presented for the urokinase groups as mean values ± SD (n = 5). ns: not significant, *p < 0.05, **p < 0.01, ****p < 0.0001).